Medpace Holdings Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B). The key difference: Medpace Holdings Inc is far larger — about 7.5× ProShares UltraPro Short QQQ ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| MEDP | SQQQ | |
|---|---|---|
Market Cap | $16.82B | $2.23B |
Volume | 223,093 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $89.43 |
52-Week Low | $393.42 | $31.83 |
Typical Hold Time | 14 Days | 12 Days |
Enterprise Value | $16.44B | — |
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
SQQQ (ProShares UltraPro Short QQQ) trades at $33.37, up 4.02% today, reflecting its bearish positioning against the Nasdaq 100. Technical indicators show a predominantly bearish signal with moving averages indicating selling pressure, while oscillators remain neutral. The ETF serves as a leveraged short tool for hedging QQQ exposure, with recent news highlighting its strategic use in portfolio protection amid tech sector volatility.
The outlook for SQQQ remains tied to Nasdaq 100 performance, offering potential gains during market downturns but carrying high risk due to daily rebalancing and decay. Key risks include rapid market reversals and the structural challenges of leveraged inverse ETFs. Investor sentiment is cautious, with media coverage emphasizing its role as a hedging instrument rather than a long-term hold.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →